Emcure Pharmaceuticals Ltd

Meeting Details

• Date and time: August 06, 2026 at 4:00 p.m. IST.
• Mode: teleconference/virtual (listen-only during remarks; conference recording).
• Event: Emcure Q1 FY27 Earnings Conference Call.

Participants

• MD & CEO: Satish Mehta.
• CFO: Tajuddin Shaikh.
• WTD & COO: Samit Mehta.
• President, Corporate Development & Strategy: Vik Thapar.
• Executive VP, Corporate Development & Strategy: Piyush Nahar.
• Head, Investor Relations: Saurabh Paliwal.

Purpose

• Purpose: discuss Q1 FY27 results and governance updates.

Availability

• Transcript and presentation will be available on the company website.

USFDA Sanand facility inspection update

• USFDA conducted inspection at Emcure's Sanand, Ahmedabad facility from May 6–15, 2026.
• Emcure received the Establishment Inspection Report (EIR) from USFDA.
• USFDA classified inspection status as Voluntary Action Indicated (VAI) and closed the inspection.
• Facility located at G.I.D.C., Taluka Sanand, Ahmedabad.
• Update date: August 8, 2026.

Meeting Details

• Aug 12, 2026: Emkay Confluence Conference 2026; city not specified.
• Aug 18, 2026: Motilal Oswal 22nd Annual Investor Conference; Mumbai; Group and One-on-One.
• Sep 01, 2026: Elara India Dialogue Conference 2026; city not specified.
• Sep 17, 2026: Kotak Healthcare Forum 2026; city not specified.
• Sep 22, 2026: 11th Annual J.P. Morgan Conference India; city not specified.

Participants

• Company officials (roles not specified) to participate in all listed meetings.

Purpose

• Intimation of schedule of Analyst/Investor Meetings with Emcure officials.

Meeting Details

• Date: August 06, 2026.
• Type/Mode: Group earnings call; audio recording.
• Organizer: Emcure Pharmaceuticals Limited.
• Recording availability: Audio recording published on company website.

Participants

• Key company participant: Company Secretary & Compliance Officer.

Purpose

• Purpose: Earnings call for Q1 FY27 results.

Additional Notes

• No transcript or presentation indicated.

Dividend record date and payout details

• Record Date: 04 September 2026 for entitlement to Final Dividend.
• Final dividend: Rs 3.60 per equity share (face value Rs 10), 36%.
• Dividend payable within 30 days from AGM approval, subject to TDS.
• AGM on 21 September 2026 will consider the dividend.

Berjis Desai exits as Chairman and Director

• Berjis Desai ceases as Chairman and Director after AGM conclusion.
• Reason: unwilling to seek re-appointment due to National Commission for Minorities appointment.
• Cessation takes effect at the conclusion of the ensuing AGM.
• Also ceases existing Committee positions held by him.

Raghu Kumar appointed Independent Director

• Raghu Kumar appointed as Additional Director (Non-Executive & Independent) from Aug 06, 2026.
• Independent Director for first term of three years from Aug 06, 2026.
• Subject to Members' approval at ensuing AGM (Sept 21, 2026).
• Not debarred; not related to any Director or KMP.
• Brief profile: four decades in pharma; leadership roles at Allergan, Novartis, Bayer.
• Disclosures: not related to any Director.

Satish Mehta to become Chairman

• Satish Mehta appointed Chairman; effective from AGM conclusion.
• Position: Managing Director & CEO.
• Reason: retirement of Berjis Desai.
• Relationship: Satish Mehta is father of Samit Mehta and Namita Thapar.
• Effective from the conclusion of the AGM; Sept 21, 2026.
• Term not specified.

Business Overview

• Pharma group with domestic and international operations.
• Gennova Biopharmaceuticals becomes wholly-owned to anchor biologics/biosimilars.
• Leadership changes: Satish Mehta to Chairman; Samit Mehta appointed COO.

Operational Highlights

• International revenue rose 34.2% YoY to ₹14.85bn; 58% of total.
• Domestic revenue up 10.2% YoY; growth across CNS and cardio-metabolics.
• RoW: 15+ products approved across Asia, Africa, LATAM.
• MSD license: royalty-free non-exclusive licensing for alimatravir PrEP candidate.
• Samit Mehta to lead Gennova as CEO; strengthens biologics focus.

Financial Performance

• Revenue from operations ₹25.8bn, up 22.8% YoY.
• Domestic ₹10.95bn; International ₹14.85bn, up 34.2% YoY.
• EBITDA ₹5.08bn; EBITDA margin 19.7%.
• PAT ₹2.93bn; PAT margin 11.3%.
• Gross profit ₹15.07bn; gross margin 58.4%.
• International contribution 58% of revenue.

Governance & Leadership

• Satish Mehta to become Chairman after AGM; remains MD & CEO.
• Samit Mehta appointed COO; oversees R&D, operations, licensing.
• Gennova Biopharmaceuticals now wholly-owned; Samit Mehta to lead as CEO.

Strategic Priorities & Outlook

• International growth remains core driver; Europe, RoW, Canada fueling growth.
• Product pipeline visibility supported by ongoing base and new business opportunities.
• Product launches and new territories expansion across Asia, Africa, LATAM.

Risks & Mitigation

• Regulatory changes and approvals delays impacting timelines.
• Currency fluctuations could affect costs and revenue.
• Supply chain challenges pose operational risk.
• Competitive pressures and technology changes in pharma landscape.

Consolidated results

• Consolidated revenue from operations for Q1 FY27: INR 25,804 million, up 22.8% YoY.
• EBITDA was INR 5,080 million with a 19.7% margin.
• PAT stood at INR 2,925 million with an 11.3% margin.
• Gross margin was 58.4%, down 340 bps YoY.
• Domestic revenue INR 10,953 million; International INR 14,851 million.
• EU revenue INR 5,367 million; CA revenue INR 4,266 million.
• RoW revenue INR 5,218 million.
• R&D investment INR 904 million, about 3.5% of revenue.
• Net debt at INR 11,026 million.

Standalone results snapshot

• Standalone revenue from operations: INR 14,509.31 million.
• Standalone PAT: INR 2,001.08 million.
• Earnings per share (basic/diluted): INR 10.55.

Geography & mix

• Domestic revenue: INR 10,953 million; International revenue: INR 14,851 million.
• EU revenue: INR 5,367 million; Canada: INR 4,266 million.
• RoW revenue: INR 5,218 million.

R&D & strategic updates

• 15+ product approvals across developed and emerging markets.
• Licensed SHetA2 HPV CIN candidate from ICMR in July 2026.
• MSD license to sell alimatravir PrEP in 129 countries (July 2026).
• Gennova stake: acquired 12.05% minority stake; now wholly owned (July 21, 2026).
• Gennova mRNA business slump-sale transfer for INR 1,395 million.
• Samit Mehta appointed CEO of Gennova.

M&A & corporate actions

• Gennova became a wholly owned subsidiary as of July 21, 2026.

Outlook & management commentary

• FY27 focus on delivering the five-year plan; Q1 signals strength.

Business model & scale

• Pharma group present in 80+ countries.

Financial results approved

• Unaudited standalone and consolidated Q1 FY27 results approved for quarter ended June 30, 2026.
• Audit Committee reviewed results; Limited Review by B S R & Co. LLP enclosed.
• Press release outlining results updates enclosed as Annexure B.

Governance and board changes

• Berjis Desai to retire at the ensuing AGM; ceases as Chairman and director.
• Satish Mehta to become Chairman from AGM conclusion.
• Raghu Kumar appointed Additional Director (Non-Executive Independent), effective August 6, 2026.
• Reconstitution of Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee from AGM conclusion.
• AGM date to be September 21, 2026.

Management appointments

• Samit Mehta appointed Chief Operating Officer with immediate effect.
• Samit Mehta appointed CEO of Gennova post-acquisition.

Strategic transactions

• Acquisition of remaining 12.05% minority stake in Gennova completed; Gennova now wholly owned.
• Gennova mRNA business transferred under BTA dated July 10, 2026 for 1,395 million.

Regulatory disclosures and auditor remarks

• Annexure C provides SEBI LODR disclosures on director changes.
• BSR & Co. LLP issued unqualified limited review on unaudited results.
• 14 subsidiaries not reviewed; not material to the Group.